

EPA Meeting with Bromethalin and Cholecalciferol Registrants

January 10, 2022, 11 AM – 12 PM EST

Participants:

EPA (PRD): Dana Friedman, Melissa Grable, Steven Peterson, Anna Senninger, Srijana Shrestha, Julie Javier, Kent Fothergill

Registrants and consultants: Eliot Harrison, Kristine Styer (Senoret, Woodstream), Kylli Paavola, Katie Swift (Liphatech), Craig Riekens, April Vingum (Bell Laboratories), Susan Westra, Linda O'Connor (Neogen, HACCO), Jane Rothwell (The Scotts Company), Rebecca Willis, Jonathan Berger (BASF)

On January 10th, 2022, EPA met with bromethalin and cholecalciferol registrants. The registrants were informed that due to the similarities in use and potential risk of these two non-anticoagulant rodenticides there will be one Proposed Interim Decision (PID) for both chemicals. The timing of registration review activities and upcoming Endangered Species Act (ESA) Draft Biological Evaluations were presented. Proposed human health and ecological mitigation measures were discussed, as well as potential early ESA mitigation. PRD intends to complete the PID in March 2022. EPA plans on completing Draft Biological Evaluations for the rodenticides in 2023. Final BEs are expected in 2024.